Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma

We report a case showing the long-term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow-up studies showed smoldering progression of metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hayoung, Chang, Jinsun, Shin, Hong-Joon, Park, Cheol-Kyu, Oh, In-Jae, Kim, Kyu-Sik, Kim, Young-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448482/
https://www.ncbi.nlm.nih.gov/pubmed/26273363
http://dx.doi.org/10.1111/1759-7714.12171
_version_ 1782373710901018624
author Choi, Hayoung
Chang, Jinsun
Shin, Hong-Joon
Park, Cheol-Kyu
Oh, In-Jae
Kim, Kyu-Sik
Kim, Young-Chul
author_facet Choi, Hayoung
Chang, Jinsun
Shin, Hong-Joon
Park, Cheol-Kyu
Oh, In-Jae
Kim, Kyu-Sik
Kim, Young-Chul
author_sort Choi, Hayoung
collection PubMed
description We report a case showing the long-term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow-up studies showed smoldering progression of metastatic lesions, continued treatment with gefitinib controlled pulmonary adenocarcinoma for more than six years.
format Online
Article
Text
id pubmed-4448482
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-44484822015-08-13 Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma Choi, Hayoung Chang, Jinsun Shin, Hong-Joon Park, Cheol-Kyu Oh, In-Jae Kim, Kyu-Sik Kim, Young-Chul Thorac Cancer Case Reports We report a case showing the long-term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow-up studies showed smoldering progression of metastatic lesions, continued treatment with gefitinib controlled pulmonary adenocarcinoma for more than six years. BlackWell Publishing Ltd 2015-03 2015-03-02 /pmc/articles/PMC4448482/ /pubmed/26273363 http://dx.doi.org/10.1111/1759-7714.12171 Text en © 2014 The Authors. Thoracic Cancer published by Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Choi, Hayoung
Chang, Jinsun
Shin, Hong-Joon
Park, Cheol-Kyu
Oh, In-Jae
Kim, Kyu-Sik
Kim, Young-Chul
Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
title Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
title_full Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
title_fullStr Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
title_full_unstemmed Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
title_short Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
title_sort clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448482/
https://www.ncbi.nlm.nih.gov/pubmed/26273363
http://dx.doi.org/10.1111/1759-7714.12171
work_keys_str_mv AT choihayoung clinicallybeneficialcontinuedtreatmentwithgefitinibafterasymptomaticprogressionoflungadenocarcinoma
AT changjinsun clinicallybeneficialcontinuedtreatmentwithgefitinibafterasymptomaticprogressionoflungadenocarcinoma
AT shinhongjoon clinicallybeneficialcontinuedtreatmentwithgefitinibafterasymptomaticprogressionoflungadenocarcinoma
AT parkcheolkyu clinicallybeneficialcontinuedtreatmentwithgefitinibafterasymptomaticprogressionoflungadenocarcinoma
AT ohinjae clinicallybeneficialcontinuedtreatmentwithgefitinibafterasymptomaticprogressionoflungadenocarcinoma
AT kimkyusik clinicallybeneficialcontinuedtreatmentwithgefitinibafterasymptomaticprogressionoflungadenocarcinoma
AT kimyoungchul clinicallybeneficialcontinuedtreatmentwithgefitinibafterasymptomaticprogressionoflungadenocarcinoma

Ejemplares similares